Neurogene Statistics
Share Statistics
Neurogene has 14.85M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 14.85M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 4.47K |
| FTD / Avg. Volume | 1.24% |
Short Selling Information
The latest short interest is 914.19K, so 6.15% of the outstanding shares have been sold short.
| Short Interest | 914.19K |
| Short % of Shares Out | 6.15% |
| Short % of Float | 7.91% |
| Short Ratio (days to cover) | 7.15 |
Valuation Ratios
The PE ratio is -6.84 and the forward PE ratio is -8.62.
| PE Ratio | -6.84 |
| Forward PE | -8.62 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.34 |
| P/FCF Ratio | -4.8 |
| PEG Ratio | n/a |
Enterprise Valuation
Neurogene Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 8.72, with a Debt / Equity ratio of 0.
| Current Ratio | 8.72 |
| Quick Ratio | 8.72 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -4631.92 |
Financial Efficiency
Return on equity (ROE) is -0.2% and return on capital (ROIC) is -27.48%.
| Return on Equity (ROE) | -0.2% |
| Return on Assets (ROA) | -0.16% |
| Return on Capital (ROIC) | -27.48% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -399.09K |
| Employee Count | 91 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 70.06% in the last 52 weeks. The beta is 0, so Neurogene 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | 70.06% |
| 50-Day Moving Average | 40.06 |
| 200-Day Moving Average | 38.3 |
| Relative Strength Index (RSI) | 39.79 |
| Average Volume (20 Days) | 359.96K |
Income Statement
In the last 12 months, Neurogene had revenue of $0 and earned -$36.32M in profits. Earnings per share was $-2.83.
| Revenue | 0 |
| Gross Profit | -3.26M |
| Operating Income | -55.58M |
| Net Income | -36.32M |
| EBITDA | -52.29M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.83 |
Balance Sheet
The company has $148.21M in cash and $16.25M in debt, giving a net cash position of $131.96M.
| Cash & Cash Equivalents | 148.21M |
| Total Debt | 16.25M |
| Net Cash | 131.96M |
| Retained Earnings | -187.15M |
| Total Assets | 164.12M |
| Working Capital | 127.85M |
Cash Flow
In the last 12 months, operating cash flow was -$51.42M and capital expenditures -$321.00K, giving a free cash flow of -$51.74M.
| Operating Cash Flow | -51.42M |
| Capital Expenditures | -321.00K |
| Free Cash Flow | -51.74M |
| FCF Per Share | -4.03 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
NGNE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -12.09% |
| FCF Yield | -14.89% |
Analyst Forecast
The average price target for NGNE is $60, which is 156.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $60 |
| Price Target Difference | 156.4% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Dec 19, 2023. It was a backward split with a ratio of 1:4.
| Last Split Date | Dec 19, 2023 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | 4.8 |
| Piotroski F-Score | 1 |